Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage immunotherapy company focused on oncology, has scheduled a conference call and webcast for Friday, March 7, 2025, at 8:30 a.m. ET. During this event, the company will provide a corporate update and discuss financial results for the fourth quarter and full year 2024.
Investors and interested parties can access the call through several options:
- North American Toll-Free: (888) 510-2154
- International: (437) 900-0527
- Conference ID: 48422
- RapidConnect option available for joining without operator assistance
A webcast will be available on the Investor Relations page of Oncolytics' website and will remain archived for three months. Additionally, a dial-in replay will be accessible for one week following the call using replay code: 48422#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), una delle principali aziende di immunoterapia in fase clinica focalizzata sull'oncologia, ha programmato una conferenza telefonica e un webcast per venerdì 7 marzo 2025, alle 8:30 ET. Durante questo evento, l'azienda fornirà un aggiornamento aziendale e discuterà i risultati finanziari del quarto trimestre e dell'intero anno 2024.
Gli investitori e le parti interessate possono accedere alla chiamata attraverso diverse opzioni:
- Numero verde nordamericano: (888) 510-2154
- Internazionale: (437) 900-0527
- ID conferenza: 48422
- Opzione RapidConnect disponibile per partecipare senza assistenza dell'operatore
Un webcast sarà disponibile nella pagina delle Relazioni con gli Investitori del sito web di Oncolytics e rimarrà archiviato per tre mesi. Inoltre, una registrazione della chiamata sarà accessibile per una settimana dopo la chiamata utilizzando il codice di riproduzione: 48422#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), una de las principales empresas de inmunoterapia en etapa clínica enfocada en oncología, ha programado una conferencia telefónica y un webcast para el viernes 7 de marzo de 2025, a las 8:30 a.m. ET. Durante este evento, la empresa proporcionará una actualización corporativa y discutirá los resultados financieros del cuarto trimestre y del año completo 2024.
Los inversores y partes interesadas pueden acceder a la llamada a través de varias opciones:
- Número gratuito de América del Norte: (888) 510-2154
- Internacional: (437) 900-0527
- ID de conferencia: 48422
- Opción RapidConnect disponible para unirse sin asistencia del operador
Un webcast estará disponible en la página de Relaciones con Inversores del sitio web de Oncolytics y permanecerá archivado durante tres meses. Además, una grabación de la llamada estará accesible durante una semana después de la llamada utilizando el código de reproducción: 48422#.
온콜리틱스 바이오텍 (NASDAQ: ONCY) (TSX: ONC), 종양학에 초점을 맞춘 주요 임상 단계 면역 요법 회사는 2025년 3월 7일 금요일 오전 8시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 이 행사 동안 회사는 기업 업데이트를 제공하고 2024년 4분기 및 전체 연도의 재무 결과를 논의할 것입니다.
투자자 및 관심 있는 당사자는 여러 가지 방법으로 전화를 받을 수 있습니다:
- 북미 무료 전화: (888) 510-2154
- 국제 전화: (437) 900-0527
- 컨퍼런스 ID: 48422
- 운영자 도움 없이 참여할 수 있는 RapidConnect 옵션 제공
온콜리틱스 웹사이트의 투자자 관계 페이지에서 웹캐스트를 이용할 수 있으며, 3개월 동안 보관됩니다. 또한, 통화 후 일주일 동안 재생 코드: 48422#를 사용하여 다이얼인 리플레이에 접근할 수 있습니다.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), une entreprise de premier plan dans le domaine de l'immunothérapie en phase clinique axée sur l'oncologie, a programmé une conférence téléphonique et un webinaire pour vendredi 7 mars 2025, à 8h30 ET. Lors de cet événement, l'entreprise fournira une mise à jour de l'entreprise et discutera des résultats financiers pour le quatrième trimestre et l'année complète 2024.
Les investisseurs et les parties intéressées peuvent accéder à l'appel par plusieurs options :
- Numéro sans frais nord-américain : (888) 510-2154
- International : (437) 900-0527
- ID de conférence : 48422
- Option RapidConnect disponible pour rejoindre sans assistance d'un opérateur
Un webinaire sera disponible sur la page des Relations avec les Investisseurs du site Web d'Oncolytics et restera archivé pendant trois mois. De plus, un enregistrement de l'appel sera accessible pendant une semaine après l'appel en utilisant le code de rediffusion : 48422#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), ein führendes Unternehmen für klinische Immuntherapie mit dem Schwerpunkt auf Onkologie, hat eine Telefonkonferenz und einen Webcast für Freitag, den 7. März 2025, um 8:30 Uhr ET angesetzt. Während dieser Veranstaltung wird das Unternehmen ein Unternehmensupdate geben und die finanziellen Ergebnisse für das vierth Quartal und das gesamte Jahr 2024 besprechen.
Investoren und interessierte Parteien können die Konferenz über mehrere Optionen erreichen:
- Nordamerikanische gebührenfreie Nummer: (888) 510-2154
- International: (437) 900-0527
- Konferenz-ID: 48422
- RapidConnect-Option verfügbar, um ohne Unterstützung des Operators beizutreten
Ein Webcast wird auf der Investor-Relations-Seite der Website von Oncolytics verfügbar sein und für drei Monate archiviert bleiben. Darüber hinaus wird eine Rückrufaufnahme für eine Woche nach dem Anruf mit dem Rückrufcode: 48422# zugänglich sein.
- None.
- None.
Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET
Conference Call & Webcast
Date: Friday, March 7, 2025
Time: 8:30 a.m. ET
Dial In – North American Toll-Free: (888) 510-2154
Dial In – International: (437) 900-0527
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 48422
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
Logo: https://mma.prnewswire.com/media/2408622/5171389/Oncolytics_Biotech_Inc_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-302384064.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When will Oncolytics Biotech (ONCY) release its Q4 and full year 2024 financial results?
How can investors access the ONCY earnings call on March 7, 2025?
Will there be a replay available for Oncolytics Biotech's (ONCY) Q4 2024 earnings call?
What topics will Oncolytics Biotech (ONCY) cover during its March 7, 2025 conference call?
